Pyrimido[1′,6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine compounds as CK2 inhibitors
Pyrimido[1′,6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine compounds as CK2 inhibitors
-
US 12,173,005 B1
-
الصحة - Health
-
2024
-
مكتب البراءات الأمريكي - US Patent Office
-
Tratrat; Christophe (Al-Ahsa, SA), Haroun; Michelyne (Al-Ahsa, SA)
-
Novel pyrimido[1′,6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrimido[1′,6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.